<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
      <PMID Version="1">35608068</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1744-5116</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>60</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Pharmaceutical biology</Title>
          <ISOAbbreviation>Pharm Biol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Effect of Er Miao San on peritoneal macrophage polarisation through the miRNA-33/NLRP3 signalling pathway in a rat model of adjuvant arthritis.</ArticleTitle>
        <Pagination>
          <StartPage>846</StartPage>
          <EndPage>853</EndPage>
          <MedlinePgn>846-853</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/13880209.2022.2066700</ELocationID>
        <Abstract>
          <AbstractText Label="CONTEXT" NlmCategory="UNASSIGNED">Er Miao San (EMS) is a formulation that contains <i>Atractylodis Rhizoma</i> and <i>Phellodendri Cortex</i> in 1:1 ratio, and is commonly used to treat rheumatoid arthritis (RA) and other inflammatory diseases.</AbstractText>
          <AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">We investigated the mechanism of action and effects of EMS on peritoneal macrophage differentiation in a rat model of adjuvant arthritis (AA).</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="UNASSIGNED">EMS (3, 1.5 and 0.75 g/kg; once daily) and methotrexate (0.5 mg/kg; once every 3 days) were administered orally from days 21 to 35 after immunisation. Paw swelling and arthritis index were measured; pathological changes in the ankle joint were observed using x-ray and haematoxylin eosin staining. The ratio of CD86/CD206 in macrophages was detected by flow cytometry. Examination of the miRNA-33/NLRP3 signalling pathway was examined by RT-qPCR and western blotting. The levels of cytokines in the serum and cell supernatants were tested by ELISA.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">EMS significantly reduced the AA index in rats (from 11.0 to 9.3) and pathological changes in the ankle joint (from 3.8 to 1.4). The ratio of CD86/CD206 was reduced, and polarisation to M1 improved (from 0.9 to 0.6) in macrophages of EMS-treated rats. EMS downregulated the miRNA-33/NLRP3 pathway. Furthermore, EMS treatment increased IL-10 and TGF-β levels in the serum and supernatant of macrophages of AA rats and simultaneously decreased the levels of IL-1β and TNF-α.</AbstractText>
          <AbstractText Label="DISCUSSION AND CONCLUSIONS" NlmCategory="UNASSIGNED">Our results suggest that EMS may reduce macrophage polarisation to the M1 inflammatory phenotype by downregulating the miRNA-33/NLRP3 pathway in AA rats. These findings may provide new insights into the treatment of RA.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Min</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Anhui Province Key Laboratory of Chinese Medicinal Formula, Hefei, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Anhui Province Key Laboratory of Research &amp; Development of Chinese Medicine, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Meng</LastName>
            <ForeName>Xiangwen</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Anhui Province Key Laboratory of Chinese Medicinal Formula, Hefei, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Anhui Province Key Laboratory of Research &amp; Development of Chinese Medicine, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xuan</LastName>
            <ForeName>Zihua</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Anhui Province Key Laboratory of Chinese Medicinal Formula, Hefei, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Anhui Province Key Laboratory of Research &amp; Development of Chinese Medicine, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Simeng</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Anhui Province Key Laboratory of Chinese Medicinal Formula, Hefei, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Anhui Province Key Laboratory of Research &amp; Development of Chinese Medicine, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Jin</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Anhui Province Key Laboratory of Chinese Medicinal Formula, Hefei, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Anhui Province Key Laboratory of Research &amp; Development of Chinese Medicine, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Zhiluo</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Anhui Province Key Laboratory of Chinese Medicinal Formula, Hefei, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Anhui Province Key Laboratory of Research &amp; Development of Chinese Medicine, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Jiayu</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Anhui Province Key Laboratory of Chinese Medicinal Formula, Hefei, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Anhui Province Key Laboratory of Research &amp; Development of Chinese Medicine, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jia</LastName>
            <ForeName>Xiaoyi</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Anhui Province Key Laboratory of Chinese Medicinal Formula, Hefei, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Anhui Province Key Laboratory of Research &amp; Development of Chinese Medicine, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Pharm Biol</MedlineTA>
        <NlmUniqueID>9812552</NlmUniqueID>
        <ISSNLinking>1388-0209</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">NLR family</Keyword>
        <Keyword MajorTopicYN="N">anti-inflammatory agents</Keyword>
        <Keyword MajorTopicYN="N">inflammasomes</Keyword>
        <Keyword MajorTopicYN="N">pyrin domain-containing 3 protein</Keyword>
        <Keyword MajorTopicYN="N">rheumatoid arthritis</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>5</Hour>
          <Minute>53</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35608068</ArticleId>
        <ArticleId IdType="doi">10.1080/13880209.2022.2066700</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
      <PMID Version="1">35608068</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1744-5116</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>60</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Pharmaceutical biology</Title>
          <ISOAbbreviation>Pharm Biol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Effect of Er Miao San on peritoneal macrophage polarisation through the miRNA-33/NLRP3 signalling pathway in a rat model of adjuvant arthritis.</ArticleTitle>
        <Pagination>
          <StartPage>846</StartPage>
          <EndPage>853</EndPage>
          <MedlinePgn>846-853</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/13880209.2022.2066700</ELocationID>
        <Abstract>
          <AbstractText Label="CONTEXT" NlmCategory="UNASSIGNED">Er Miao San (EMS) is a formulation that contains <i>Atractylodis Rhizoma</i> and <i>Phellodendri Cortex</i> in 1:1 ratio, and is commonly used to treat rheumatoid arthritis (RA) and other inflammatory diseases.</AbstractText>
          <AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">We investigated the mechanism of action and effects of EMS on peritoneal macrophage differentiation in a rat model of adjuvant arthritis (AA).</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="UNASSIGNED">EMS (3, 1.5 and 0.75 g/kg; once daily) and methotrexate (0.5 mg/kg; once every 3 days) were administered orally from days 21 to 35 after immunisation. Paw swelling and arthritis index were measured; pathological changes in the ankle joint were observed using x-ray and haematoxylin eosin staining. The ratio of CD86/CD206 in macrophages was detected by flow cytometry. Examination of the miRNA-33/NLRP3 signalling pathway was examined by RT-qPCR and western blotting. The levels of cytokines in the serum and cell supernatants were tested by ELISA.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">EMS significantly reduced the AA index in rats (from 11.0 to 9.3) and pathological changes in the ankle joint (from 3.8 to 1.4). The ratio of CD86/CD206 was reduced, and polarisation to M1 improved (from 0.9 to 0.6) in macrophages of EMS-treated rats. EMS downregulated the miRNA-33/NLRP3 pathway. Furthermore, EMS treatment increased IL-10 and TGF-β levels in the serum and supernatant of macrophages of AA rats and simultaneously decreased the levels of IL-1β and TNF-α.</AbstractText>
          <AbstractText Label="DISCUSSION AND CONCLUSIONS" NlmCategory="UNASSIGNED">Our results suggest that EMS may reduce macrophage polarisation to the M1 inflammatory phenotype by downregulating the miRNA-33/NLRP3 pathway in AA rats. These findings may provide new insights into the treatment of RA.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Min</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Anhui Province Key Laboratory of Chinese Medicinal Formula, Hefei, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Anhui Province Key Laboratory of Research &amp; Development of Chinese Medicine, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Meng</LastName>
            <ForeName>Xiangwen</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Anhui Province Key Laboratory of Chinese Medicinal Formula, Hefei, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Anhui Province Key Laboratory of Research &amp; Development of Chinese Medicine, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xuan</LastName>
            <ForeName>Zihua</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Anhui Province Key Laboratory of Chinese Medicinal Formula, Hefei, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Anhui Province Key Laboratory of Research &amp; Development of Chinese Medicine, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Simeng</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Anhui Province Key Laboratory of Chinese Medicinal Formula, Hefei, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Anhui Province Key Laboratory of Research &amp; Development of Chinese Medicine, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Jin</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Anhui Province Key Laboratory of Chinese Medicinal Formula, Hefei, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Anhui Province Key Laboratory of Research &amp; Development of Chinese Medicine, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Zhiluo</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Anhui Province Key Laboratory of Chinese Medicinal Formula, Hefei, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Anhui Province Key Laboratory of Research &amp; Development of Chinese Medicine, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Jiayu</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Anhui Province Key Laboratory of Chinese Medicinal Formula, Hefei, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Anhui Province Key Laboratory of Research &amp; Development of Chinese Medicine, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jia</LastName>
            <ForeName>Xiaoyi</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Anhui Province Key Laboratory of Chinese Medicinal Formula, Hefei, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Anhui Province Key Laboratory of Research &amp; Development of Chinese Medicine, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Pharm Biol</MedlineTA>
        <NlmUniqueID>9812552</NlmUniqueID>
        <ISSNLinking>1388-0209</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">NLR family</Keyword>
        <Keyword MajorTopicYN="N">anti-inflammatory agents</Keyword>
        <Keyword MajorTopicYN="N">inflammasomes</Keyword>
        <Keyword MajorTopicYN="N">pyrin domain-containing 3 protein</Keyword>
        <Keyword MajorTopicYN="N">rheumatoid arthritis</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>5</Hour>
          <Minute>53</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35608068</ArticleId>
        <ArticleId IdType="doi">10.1080/13880209.2022.2066700</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
